micro-community-banner
 
  • Saved

3mo
Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group - PubMed

Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40497316/

Type 2 diabetes (T2D) is a pandemic and strongly impact patients' prognosis. Several barriers may hamper the achievement of good glycaemic control, which is the aim of diabetes care. These...

Type 2 diabetes management faces barriers to glycaemic control. Continuous glucose monitoring enhances glucose pattern detection, hypoglycaemia prevention, and control, with growing evidence supporting broader use beyond current guidelines.

  • Saved

3mo
Young-onset type 2 diabetes-Epidemiology, pathophysiology, and management - PubMed

Young-onset type 2 diabetes-Epidemiology, pathophysiology, and management - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40411309/

The prevalence and incidence of young-onset type 2 diabetes is increasing globally, especially in low- and middle-income countries, and predominantly affects non-White ethnic and racial populations. Young-onset type 2 is...

Young-onset type 2 diabetes is rising globally, especially among non-White populations. It involves complex risk factors, poor representation in trials, and unmet needs in care, prevention, and precision management.

  • Saved

3mo
Platelet-Rich Plasma in Diabetic Foot Ulcer Healing: Contemplating the Facts - PubMed

Platelet-Rich Plasma in Diabetic Foot Ulcer Healing: Contemplating the Facts - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39684575/

Diabetic foot ulcers (DFUs), debilitating complication of diabetes, often lead to amputation even in the presence of current advanced treatment for DFUs. Platelet-rich plasma (PRP) containing growth factors and other...

PRP is a promising, safe therapy for diabetic foot ulcers, but variability in constituent concentrations affects outcomes; standardized protocols and further trials are needed to optimize healing efficacy.

  • Saved

4mo
Type 2 diabetes, heart failure and the treatment of their comorbidity - PubMed

Type 2 diabetes, heart failure and the treatment of their comorbidity - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39641257/

Both heart failure and type 2 diabetes are prevalent conditions and share similar pathogenesis, risk factors, and treatment medications. This review aims to inform clinical practice by summarizing the interaction...

This review highlights the interplay between heart failure and type 2 diabetes, emphasizing SGLT2 inhibitors’ dual benefits, shared treatment strategies, and the importance of personalized, evidence-based clinical decision-making.

  • Saved

4mo
GLP-1 Therapies in Metabolic and Hormonal Health: ENDO 2025 Insights

At ENDO 2025, Dr. Monica Laronda (Lurie Children’s Hospital, Northwestern University) highlighted emerging research investigating how GLP-1 therapies and rising obesity rates may influence puberty onset, menarche timing, and sex-specific disease expression—particularly in adolescents with high BMI or genetic susceptibility. She also discussed environmental and epigenetic drivers of endocrine disruption and underscored the need to consider sex as a biological variable in metabolic research. Dr. Shellsea Portillo (St. Louis University Hospital) presented retrospective data indicating that GLP-1–associated weight loss significantly improved testosterone levels in obese men with type 2 diabetes, suggesting a possible avenue for further exploration as a non-hormonal strategy for managing obesity-related hypogonadism. Together, these insights underscore GLP-1’s emerging but preliminary role in reproductive and metabolic endocrine health.